Skip to main content
SpringerLink
Log in

Osteoprotegerin

  • Living reference work entry
  • First Online:
Encyclopedia of Signaling Molecules

  • 55 Accesses

Synonyms

Follicular dendritic cell-derived receptor-1 (FDCR-1); Osteoclastogenesis inhibitory factor (OCIF); Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B); Tumor necrosis factor receptor-like molecule-1 (TR-1)

Historical Background

It has been estimated that around 10% of total bone mass is renewed per year leading to a full replacement of the bone tissue every 10 years. This biological mechanism called “bone remodeling” plays a central role in calcium and phosphorus homeostasis and is the result of a balance between osteoclast and osteoblast activities. Indeed, osteoclasts originating from hematopoietic stem cells resorb bone (Rousselle and Heymann 2002); and in contrast, osteoblasts, which come from mesenchymal stem cells, are specialized in the formation of new mineralized extracellular matrix (Dechaseaux et al. 2009). For many years, a central regulation based on hormone network including parathyroid hormone (PTH) or calcitonin has been considered as the key...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9. doi:10.1038/36593.

    Article  CAS  PubMed  Google Scholar 

  • Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev. 2013;24:401–9. doi:10.1016/j.cytogfr.2013.06.001.

    Article  PubMed  Google Scholar 

  • Baud’huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci. 2007;64:2334–50. doi:10.1007/s00018-007-7104-0.

    Article  PubMed  Google Scholar 

  • Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66. doi:10.1359/JBMR.040305.

    Article  CAS  PubMed  Google Scholar 

  • Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, et al. Osteoprotegerin: a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost. 2011;9:834–43. doi:10.1111/j.1538-7836.2011.04207.x.

    Article  CAS  PubMed  Google Scholar 

  • Bernardi S, Bossi F, Toffoli B, Fabris B. Roles and clinical applications of opg and trail as biomarkers in cardiovascular disease. Biomed Res Int. 2016;2016:1752854. doi:10.1155/2016/1752854.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Caparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol. 2009;86:933–40. doi:10.1189/jlb.0708419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davaine JM, Quillard T, Brion R, Lapérine O, Guyomarch B, Merlini T, et al. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS One. 2014;9:e107642. doi:10.1371/journal.pone.0107642.

    Article  PubMed  PubMed Central  Google Scholar 

  • Davaine JM, Quillard T, Chatelais M, Guilbaud F, Brion R, Guyomarch B, et al. Bone like arterial calcification in femoral atherosclerotic lesions: prevalence and role of osteoprotegerin and pericytes. Eur J Vasc Endovasc Surg. 2016;51:259–67. doi:10.1016/j.ejvs.2015.10.004.

    Article  PubMed  Google Scholar 

  • Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.

    Article  CAS  PubMed  Google Scholar 

  • Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692–6. doi:10.1038/nature04524.

    Article  CAS  PubMed  Google Scholar 

  • Kondegowda NG, Fenutria R, Pollack IR, Orthofer M, Garcia-Ocaña A, Penninger JM, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway. Cell Metab. 2015;22:77–85. doi:10.1016/j.cmet.2015.05.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  CAS  PubMed  Google Scholar 

  • Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta. 2010;1805:17–24. doi:10.1016/j.bbcan.2009.08.004.

    CAS  PubMed  Google Scholar 

  • Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964–71.

    Article  CAS  PubMed  Google Scholar 

  • Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004;15:2834–41. doi:10.1091/mbc.E04-01-0059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rousselle AV, Heymann D. Osteoclastic acidification pathways during bone resorption. Bone. 2002;30:533–40.

    Article  CAS  PubMed  Google Scholar 

  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.

    Article  CAS  PubMed  Google Scholar 

  • Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75.

    Article  CAS  PubMed  Google Scholar 

  • Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006;347:460–7. doi:10.1016/j.bbrc.2006.06.120.

    Article  PubMed  Google Scholar 

  • Tsuda E, Goto M, Michizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234:137–42.

    Article  CAS  PubMed  Google Scholar 

  • Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117–23.

    Article  CAS  PubMed  Google Scholar 

  • Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998a;139:1329–37. doi:10.1210/endo.139.3.5837.

    PubMed  Google Scholar 

  • Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998b;95:3597–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, et al. RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res. 2016;76(19):5857–69. doi:10.1158/0008-5472.CAN-15-2745.

    Article  CAS  PubMed  Google Scholar 

  • Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, et al. Osteoprotegerin: a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol. 2001;166:1482–91.

    Article  CAS  PubMed  Google Scholar 

  • Zofkova I, Nemcikova P, Kuklik M. Polymorphisms associated with low bone mass and high risk of atraumatic fracture. Physiol Res. 2015;64:621–31.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM, UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, University of Nantes, Nantes, France

    Dominique Heymann & Marie-Françoise Heymann

  2. Department of Oncology and Metabolism, Inserm, European Associated Laboratory “Sarcoma Research Unit”, The Medical School, University of Sheffield, Beech Hill Road, S10 2RX, Sheffield, UK

    Dominique Heymann & Marie-Françoise Heymann

Authors
  1. Dominique Heymann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Françoise Heymann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Heymann .

Editor information

Editors and Affiliations

  1. Dept. Biological Science, Department of Molecular Science and Tech College of Natural Science, Suwon, Korea (Republic of)

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this entry

Cite this entry

Heymann, D., Heymann, MF. (2016). Osteoprotegerin. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6438-9_101718-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6438-9_101718-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6438-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation